about
Hypoxia and cell cycle regulation of the von Hippel-Lindau tumor suppressorErythrocytosis-associated HIF-2alpha mutations demonstrate a critical role for residues C-terminal to the hydroxylacceptor prolineHIF1α deubiquitination by USP8 is essential for ciliogenesis in normoxiaInteraction with factor inhibiting HIF-1 defines an additional mode of cross-coupling between the Notch and hypoxia signaling pathwaysSystemic VHL gene functions and the VHL diseasepVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2The role of cullin 5-containing ubiquitin ligasesPrognostic Significance of Hypoxia-Inducible Factor Expression in Renal Cell Carcinoma: A PRISMA-compliant Systematic Review and Meta-AnalysisK11-linked ubiquitin chains as novel regulators of cell divisionAttenuating myocardial ischemia by targeting A2B adenosine receptorsHIF1A reduces acute lung injury by optimizing carbohydrate metabolism in the alveolar epitheliumAllosteric inhibition of hypoxia inducible factor-2 with small moleculesTrial Watch: Proteasomal inhibitors for anticancer therapyRenal cell carcinoma.Hypoxia inactivates the VHL tumor suppressor through PIASy-mediated SUMO modification.Determination of angptl4 mRNA as a diagnostic marker of primary and metastatic clear cell renal-cell carcinoma.The von hippel-lindau protein suppresses androgen receptor activity.The SWI/SNF Protein PBRM1 Restrains VHL-Loss-Driven Clear Cell Renal Cell Carcinoma.Human papillomavirus 16 E6 contributes HIF-1α induced Warburg effect by attenuating the VHL-HIF-1α interaction.Tumor vasculature is regulated by PHD2-mediated angiogenesis and bone marrow-derived cell recruitment.ELL is an HIF-1alpha partner that regulates and responds to hypoxia response in PC3 cells.Erythrocytosis associated with a novel missense mutation in the HIF2A gene.HIF-prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolismProtein neddylation: beyond cullin-RING ligases.Overexpression and activation of epidermal growth factor receptor in hemangioblastomas.Ubiquitin/SUMO modification regulates VHL protein stability and nucleocytoplasmic localization.Blocking the mTOR pathway: a drug discovery perspective.Clinical and functional properties of novel VHL mutation (X214L) consistent with Type 2A phenotype and low risk of renal cell carcinoma.pVHL mediates K63-linked ubiquitination of nCLU.Loss of hypoxia-inducible factor prolyl hydroxylase activity in cardiomyocytes phenocopies ischemic cardiomyopathy.Control of HIF-1alpha expression by eIF2 alpha phosphorylation-mediated translational repression.Epidemiology and risk factors for kidney cancer.Targeting hypoxia signalling for the treatment of ischaemic and inflammatory diseasesDeletion of the von Hippel-Lindau gene causes sympathoadrenal cell death and impairs chemoreceptor-mediated adaptation to hypoxia.Tumor signatures of PTHLH overexpression, high serum calcium, and poor prognosis were observed exclusively in clear cell but not non clear cell renal carcinomasUp-regulation of pVHL along with down-regulation of HIF-1α by NDRG2 expression attenuates proliferation and invasion in renal cancer cellsNew insights into the biology of renal cell carcinomaThe tumour antigen PRAME is a subunit of a Cul2 ubiquitin ligase and associates with active NFY promotersTFE3 Translocation-Associated Renal Cell Carcinoma Presenting as Avascular Necrosis of the Femur in a 19-Year-Old Patient: Case Report and Review of the Literature.Genetic and functional studies implicate HIF1α as a 14q kidney cancer suppressor gene
P2860
Q24298032-E56E868C-268B-4475-B850-31B828D723E9Q24309788-2C6B4FFC-05AB-44CD-8C6E-A76578A4F9BEQ24317014-6B1BE068-6B43-4D36-89E9-5BF46605B151Q24317627-E4DC5634-3FBF-479C-821A-2EF7D81EA504Q24605882-40EC2399-FEFD-4EF1-825E-D0DF505E3494Q24684757-0BBAA4EC-8AF7-45B7-BC25-C47482E85E5EQ26749274-15F90492-583B-4666-BA5F-956047127C58Q26781470-3A5966AF-9EC4-4C48-852E-17C0173C4B83Q26851677-C92FC8AD-42F7-4CC1-9A79-1D33FBF95236Q27006863-D7B6F463-D5C2-4D29-8ECE-0C485773818BQ27316863-D45E991E-11D7-499B-B4B3-C1B19731D3B7Q27676596-94348A7A-57CE-401B-8F5E-F4D4D2A8C1D4Q28082910-F385EB0E-006D-4381-BC57-F5897B09FE44Q30235364-58497873-3BF8-4A54-A8DB-103F78068A6AQ33543092-D2A2CF43-1EA7-48B1-81E7-81533FBAF64AQ33573577-F595BAE2-A956-470C-B178-942C64DB1A31Q33669695-FFA1A9D0-2AAD-4272-B349-944A14BB22ADQ33683959-8E25EABE-2E02-414D-B5C8-2596B97A1D92Q33755672-1F520801-22E7-4DDF-816F-64E317BAA33FQ33757944-B78158EB-E945-4A07-803A-5AED2F0983BAQ33802059-322024B4-C4B3-438B-82E5-4B91ECA6F0BCQ33829114-135B7868-60C8-455A-89F5-2E05B09FC4C4Q33926530-BF3E8AA4-B240-444B-8FC1-5130505977DBQ34042816-C3E3D30B-E1CE-48BF-8D2E-23440737BCDAQ34083790-C6A64BAE-B2AD-4F11-93C9-9756C881909AQ34115236-204D594A-661A-4E19-AF29-DF659B330E4EQ34172699-880D7C90-3ED5-4F68-AD02-772D30D49C7DQ34217763-93EDE1DD-E873-44A4-B06A-0FDA9BE0E8F5Q34245192-3B1B667B-D215-4259-8978-DC947815D490Q34271664-FA84AE70-EB2C-4C9F-B00D-FF7611EE3146Q34300719-659F6B1B-B234-46E0-A8DD-5E0E53DA2ADDQ34449963-D19597BC-5D21-4F11-A19C-892A98F31DF7Q34657382-11555A86-ADA4-468B-9E89-4775EC202DC3Q34880963-0A394E3F-AF78-462A-8B2D-5C7A4E077C2BQ35000416-5CE0084C-0054-4D8C-877D-985AB22527F2Q35078332-F0C7E2CC-AAF8-4845-8414-903EA0636A1DQ35180400-5990880E-830D-4876-AB19-AFDED30A2997Q35214905-9E853439-A270-49B3-B6AA-433E0C614E4BQ35293660-884BFBA4-DBD5-4A42-A463-06AF7BC2BAB2Q35452783-46288C0A-2558-42ED-A119-FED3C8A76B1D
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Von Hippel-Lindau disease.
@en
type
label
Von Hippel-Lindau disease.
@en
prefLabel
Von Hippel-Lindau disease.
@en
P1476
Von Hippel-Lindau disease.
@en
P304
P356
10.1146/ANNUREV.PATHOL.2.010506.092049
P577
2007-01-01T00:00:00Z